Empty vials containing a dose of the Johnson & Johnson vaccine against the COVID-19 coronavirus are lying on a table as South Africa continues its vaccination campaign at Klerksdorp Hospital on 18 February 2021.
Phill Magakoe | AFP | Getty Images
Two participants in the trial suffered severe allergic reactions shortly after receiving the Covid-19 vaccine from Johnson & Johnson, a J&J scientist told an FDA panel on Friday.
J&J was briefed on the allergic reactions for the first time on Wednesday, Macaya Douoguih, head of clinical development and medical affairs at J & J’s vaccine division Janssen, told the FDA’s advisory committee on vaccines and related biological products.
One of the people is taking part in an ongoing trial in South Africa and is developing anaphylaxis, a serious and life-threatening allergic reaction, after she received the vaccination.
She did not give details about the reaction of the second person.
“We will continue to monitor the events closely,” she told the panel.
There have been no reports of anaphylaxis in J & J’s clinical trial before. The Centers for Disease Control and Prevention is currently overseeing events as states and pharmacies roll out Pfizer and Moderna’s vaccinations.
There were 46 reports of anaphylaxis in those who received Pfizer’s vaccine, and 16 cases in those who received Moderna, according to a CDC report published on February 16th. vaccine.
The CDC asks healthcare providers to monitor patients for 15 minutes after vaccination and 30 minutes for those with a history of allergic reactions.
If someone has a severe allergic reaction after the first dose of Covid-19 vaccine, the CDC recommends that they do not receive the second dose, even if the allergic reaction was not severe enough to require emergency care.